Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: A pilot study

Henry A. Wojtczak, Gwendolyn S. Kerby, Jeffrey S. Wagener, Steven C. Copenhaver, Ronald W. Gotlin, David W H Riches, Frank J. Accurso

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Inhaled corticosteroids are commonly used in cystic fibrosis (CF), but there are few studies evaluating their safety in young children. We, therefore, prospectively administered beclomethasone diproprionate (BDP) to 12 clinically stable young children with CF to examine the safety of this therapy with respect to adrenal suppression and airway infection. To determine potential mechanisms of corticosteroid action in CF, we also examined airway markers of inflammation before and after inhaled steroid treatment. BDP 210 μg twice a day was given via spacer for 2 months. Twelve-hour serum and urine cortisols and response to low-dose synthetic ACTH cortisol stimulation were assessed. Bronchoalveolar lavage fluid (BALF) was examined pre- and posttreatment with BDP by quantitative bacteriology and indices of airway inflammation, including levels of total neutrophils, neutrophil elastase-α-1 antiprotease complexes (NEAP), CA 19-9 mucin-associated antigen, interleukin-8 (IL-8), and macrophage IL-8 mRNA. Following 2 months of treatment, serum and urine cortisol levels were unchanged. Response to low-dose ACTH cortisol stimulation was not significantly decreased at 30 min. Posttreatment BALF bacterial density was not statistically different from pretreatment; however, one patient who was initially culture negative became culture-positive with Hemophilus influenzae. BALF total neutrophil counts, corrected for epithelial lining fluid dilution, were decreased to approximately one third of pretreatment values (P = 0.03). NEAP and CA 19-9 mucin-associated antigen demonstrated similar decreases. BALF IL-8 levels and macrophage IL-8 mRNA levels were not statistically changed. These findings suggest that treatment with BDP 420 μg per day for 2 months in young children with CF does not affect urine and blood cortisol, causes no decrease in adrenal reserve, and does not result in a clinically significant increase in airway infection. In addition, the fall in bronchoalveolar lavage fluid inflammatory markers following BDP suggests possible modulation of neutrophil influx into the CF airway and provides justification for further studies of inhaled corticosteroids in CF. Pediatr Pulmonol.

Original languageEnglish (US)
Pages (from-to)293-302
Number of pages10
JournalPediatric Pulmonology
Volume32
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Beclomethasone
Cystic Fibrosis
Bronchoalveolar Lavage Fluid
Hydrocortisone
Inflammation
Interleukin-8
Leukocyte Elastase
Adrenal Cortex Hormones
Neutrophils
Urine
Mucins
Protease Inhibitors
Macrophages
Cosyntropin
Safety
Antigens
Messenger RNA
Bacteriology
Haemophilus influenzae
Therapeutics

Keywords

  • Airway inflammation
  • Bronchoalveolar lavage
  • Children
  • Cystic fibrosis
  • Inhaled corticosteroids
  • Macrophage
  • Neutrophil

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis : A pilot study. / Wojtczak, Henry A.; Kerby, Gwendolyn S.; Wagener, Jeffrey S.; Copenhaver, Steven C.; Gotlin, Ronald W.; Riches, David W H; Accurso, Frank J.

In: Pediatric Pulmonology, Vol. 32, No. 4, 2001, p. 293-302.

Research output: Contribution to journalArticle

Wojtczak, Henry A. ; Kerby, Gwendolyn S. ; Wagener, Jeffrey S. ; Copenhaver, Steven C. ; Gotlin, Ronald W. ; Riches, David W H ; Accurso, Frank J. / Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis : A pilot study. In: Pediatric Pulmonology. 2001 ; Vol. 32, No. 4. pp. 293-302.
@article{0d6cec4691e04c27be2ac95f86931948,
title = "Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: A pilot study",
abstract = "Inhaled corticosteroids are commonly used in cystic fibrosis (CF), but there are few studies evaluating their safety in young children. We, therefore, prospectively administered beclomethasone diproprionate (BDP) to 12 clinically stable young children with CF to examine the safety of this therapy with respect to adrenal suppression and airway infection. To determine potential mechanisms of corticosteroid action in CF, we also examined airway markers of inflammation before and after inhaled steroid treatment. BDP 210 μg twice a day was given via spacer for 2 months. Twelve-hour serum and urine cortisols and response to low-dose synthetic ACTH cortisol stimulation were assessed. Bronchoalveolar lavage fluid (BALF) was examined pre- and posttreatment with BDP by quantitative bacteriology and indices of airway inflammation, including levels of total neutrophils, neutrophil elastase-α-1 antiprotease complexes (NEAP), CA 19-9 mucin-associated antigen, interleukin-8 (IL-8), and macrophage IL-8 mRNA. Following 2 months of treatment, serum and urine cortisol levels were unchanged. Response to low-dose ACTH cortisol stimulation was not significantly decreased at 30 min. Posttreatment BALF bacterial density was not statistically different from pretreatment; however, one patient who was initially culture negative became culture-positive with Hemophilus influenzae. BALF total neutrophil counts, corrected for epithelial lining fluid dilution, were decreased to approximately one third of pretreatment values (P = 0.03). NEAP and CA 19-9 mucin-associated antigen demonstrated similar decreases. BALF IL-8 levels and macrophage IL-8 mRNA levels were not statistically changed. These findings suggest that treatment with BDP 420 μg per day for 2 months in young children with CF does not affect urine and blood cortisol, causes no decrease in adrenal reserve, and does not result in a clinically significant increase in airway infection. In addition, the fall in bronchoalveolar lavage fluid inflammatory markers following BDP suggests possible modulation of neutrophil influx into the CF airway and provides justification for further studies of inhaled corticosteroids in CF. Pediatr Pulmonol.",
keywords = "Airway inflammation, Bronchoalveolar lavage, Children, Cystic fibrosis, Inhaled corticosteroids, Macrophage, Neutrophil",
author = "Wojtczak, {Henry A.} and Kerby, {Gwendolyn S.} and Wagener, {Jeffrey S.} and Copenhaver, {Steven C.} and Gotlin, {Ronald W.} and Riches, {David W H} and Accurso, {Frank J.}",
year = "2001",
doi = "10.1002/ppul.1122",
language = "English (US)",
volume = "32",
pages = "293--302",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis

T2 - A pilot study

AU - Wojtczak, Henry A.

AU - Kerby, Gwendolyn S.

AU - Wagener, Jeffrey S.

AU - Copenhaver, Steven C.

AU - Gotlin, Ronald W.

AU - Riches, David W H

AU - Accurso, Frank J.

PY - 2001

Y1 - 2001

N2 - Inhaled corticosteroids are commonly used in cystic fibrosis (CF), but there are few studies evaluating their safety in young children. We, therefore, prospectively administered beclomethasone diproprionate (BDP) to 12 clinically stable young children with CF to examine the safety of this therapy with respect to adrenal suppression and airway infection. To determine potential mechanisms of corticosteroid action in CF, we also examined airway markers of inflammation before and after inhaled steroid treatment. BDP 210 μg twice a day was given via spacer for 2 months. Twelve-hour serum and urine cortisols and response to low-dose synthetic ACTH cortisol stimulation were assessed. Bronchoalveolar lavage fluid (BALF) was examined pre- and posttreatment with BDP by quantitative bacteriology and indices of airway inflammation, including levels of total neutrophils, neutrophil elastase-α-1 antiprotease complexes (NEAP), CA 19-9 mucin-associated antigen, interleukin-8 (IL-8), and macrophage IL-8 mRNA. Following 2 months of treatment, serum and urine cortisol levels were unchanged. Response to low-dose ACTH cortisol stimulation was not significantly decreased at 30 min. Posttreatment BALF bacterial density was not statistically different from pretreatment; however, one patient who was initially culture negative became culture-positive with Hemophilus influenzae. BALF total neutrophil counts, corrected for epithelial lining fluid dilution, were decreased to approximately one third of pretreatment values (P = 0.03). NEAP and CA 19-9 mucin-associated antigen demonstrated similar decreases. BALF IL-8 levels and macrophage IL-8 mRNA levels were not statistically changed. These findings suggest that treatment with BDP 420 μg per day for 2 months in young children with CF does not affect urine and blood cortisol, causes no decrease in adrenal reserve, and does not result in a clinically significant increase in airway infection. In addition, the fall in bronchoalveolar lavage fluid inflammatory markers following BDP suggests possible modulation of neutrophil influx into the CF airway and provides justification for further studies of inhaled corticosteroids in CF. Pediatr Pulmonol.

AB - Inhaled corticosteroids are commonly used in cystic fibrosis (CF), but there are few studies evaluating their safety in young children. We, therefore, prospectively administered beclomethasone diproprionate (BDP) to 12 clinically stable young children with CF to examine the safety of this therapy with respect to adrenal suppression and airway infection. To determine potential mechanisms of corticosteroid action in CF, we also examined airway markers of inflammation before and after inhaled steroid treatment. BDP 210 μg twice a day was given via spacer for 2 months. Twelve-hour serum and urine cortisols and response to low-dose synthetic ACTH cortisol stimulation were assessed. Bronchoalveolar lavage fluid (BALF) was examined pre- and posttreatment with BDP by quantitative bacteriology and indices of airway inflammation, including levels of total neutrophils, neutrophil elastase-α-1 antiprotease complexes (NEAP), CA 19-9 mucin-associated antigen, interleukin-8 (IL-8), and macrophage IL-8 mRNA. Following 2 months of treatment, serum and urine cortisol levels were unchanged. Response to low-dose ACTH cortisol stimulation was not significantly decreased at 30 min. Posttreatment BALF bacterial density was not statistically different from pretreatment; however, one patient who was initially culture negative became culture-positive with Hemophilus influenzae. BALF total neutrophil counts, corrected for epithelial lining fluid dilution, were decreased to approximately one third of pretreatment values (P = 0.03). NEAP and CA 19-9 mucin-associated antigen demonstrated similar decreases. BALF IL-8 levels and macrophage IL-8 mRNA levels were not statistically changed. These findings suggest that treatment with BDP 420 μg per day for 2 months in young children with CF does not affect urine and blood cortisol, causes no decrease in adrenal reserve, and does not result in a clinically significant increase in airway infection. In addition, the fall in bronchoalveolar lavage fluid inflammatory markers following BDP suggests possible modulation of neutrophil influx into the CF airway and provides justification for further studies of inhaled corticosteroids in CF. Pediatr Pulmonol.

KW - Airway inflammation

KW - Bronchoalveolar lavage

KW - Children

KW - Cystic fibrosis

KW - Inhaled corticosteroids

KW - Macrophage

KW - Neutrophil

UR - http://www.scopus.com/inward/record.url?scp=0034790494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034790494&partnerID=8YFLogxK

U2 - 10.1002/ppul.1122

DO - 10.1002/ppul.1122

M3 - Article

C2 - 11568990

AN - SCOPUS:0034790494

VL - 32

SP - 293

EP - 302

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 4

ER -